Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

varnimcabtagene autoleucel

A preparation of adult differentiated autologous T lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv), derived from the CD19-A3B1 hybridoma, linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. The autologous T cells were stimulated with anti-CD3 and anti-CD28 antibodies, expanded with interleukin (IL) 7 (IL-7) and IL-15, and transduced with a lentiviral vector containing the CAR gene construct. Upon administration, varnimcabtagene autoleucel target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
Synonym:autologous anti-CD19 CAR T cells ARI-0001
autologous anti-CD19 CAR-4-1BB-CD3zeta-expressing T cells ARI-0001
CD19 CAR T cells ARI-0001
CD19 CAR-T cells ARI-0001
Code name:ARI 0001
ARI-0001
ARI0001
PEI 19-187
Search NCI's Drug Dictionary